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Abstract 
Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly 
clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients 
from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No 
association could be observed between FCGR3A-158 gene polymorphism and the clinical response to 
infliximab, which was primarily defined as a decrease of ≥ 70 points in the Crohn's disease activity index or 
clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater 
decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F 
homozygotes ( -79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P= 0.043). This finding 
has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of 
anti-tumor necrosis factor agents in Crohn's disease. 




While the mechanism of action of infliximab in Crohn's disease (CD) is not completely understood, lysis of 
mononuclear cells expressing membrane tumor necrosis factor-alpha (TNF-α) through apoptosis, complement 
activation, and/or antibody-dependent cell-mediated cytotoxicity (ADCC) are suspected [1-4]. A functionally 
significant polymorphism in FCGR3A, the gene coding for FcγRIIIa, a receptor for the Fc portion of IgG 
expressed on macrophages and natural killer cells, and involved in ADCC, has been found to be associated with 
a positive response to another recombinant IgG1 antibody, ritux-imab, in non-Hodgkin's lymphoma [5]. 
Recently, it has been reported that CD patients with FCGR3A-158V/V genotype had a better biological, and 
possibly better clinical response to infliximab [6]. Specifically, the median relative decrease in C-reactive protein 
(CRP) following infliximab therapy was significantly greater in V/V homozygotes, and all patients with this 
genotype had a CRP decrease of at least 25% 4 weeks after a single infliximab infusion [6]. Confirmation of this 
finding in a large cohort was a key step before considering this genetic marker as potentially relevant for 
infliximab treatment of CD patients. We therefore tested the hypothesis of an association between FCGR3A gene 
polymorphism and response to infliximab in the prospective, randomized, controlled ACCENT I study (A 
Crohn's disease Clinical Trial Evaluating infliximab in a New long-term Treatment regimen) [7]. 
Patients and methods 
Study population 
In ACCENT I [7], 573 patients with active intestinal CD and a Crohn's disease activity index (CDAI) between 
220 and 450 received a single infusion of infliximab 5 mg/kg at baseline. At week 2, patients were randomized 
to one of three treatment regimens administered through week 46: (1) single-dose group: placebo at weeks 2 and 
6 and then every 8 weeks, (2) 5-mg/kg maintenance group: infliximab 5 mg/kg at weeks 2 and 6 and then every 
8 weeks, and (3) 10-mg/kg maintenance group: infliximab 5mg/kg at weeks 2 and 6 and then infliximab l0mg/kg 
every 8 weeks. FCGR3A-158 polymorphism was determined in 344 patients who consented to participate in this 
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substudy. 
Classification of response to infliximab 
For this analysis, clinical response was assessed at week 2, at which point all patients had received one infusion 
of infliximab 5 mg/kg. Clinical response was defined as a CDAI decrease of at least 70 points, and clinical 
remission was defined as a CDAI score lower than 150. The decrease in CDAI was also compared among patient 
genotypes. With regard to biomarkers of disease activity, serum CRP concentration data were available at weeks 
2 and 6. A positive response, assessed at both weeks 2 and 6, was defined by a CRP decrease of at least 25% 
from baseline. The actual decrease in CRP levels was also compared between patient genotypes. 
DNA analysis 
FCGR3A polymorphism was assessed using allelic discrimination by TaqMan technology (ABI 7700, Applied 
Biosystems, Foster City, California, USA) [8] after validation by an allele-specific polymerase chain reaction 
[6]. The following primers and probes were used: (1) primer sequences: FCRG3A_TG-F1 ATTCCAAAAGC-
CACACTCAAAGA and FCRG3A_TG-R1 ATGGT-GATGTTCACAGTCTCTGAAG; (2) probes: 
FCRG3A_TG-V1 CTCCCAACAAGCC VIC and FCRG3A_TG-M1 TACTCCCAAAAAGC FAM. Primers and 
probes were designed with Primer Express (Aplera, Foster City, California, USA) and synthesized through 
Applied Biosystems. The amplification conditions involved two pre-PCR steps of 2 min at 50°C and 10 min at 
95°C, followed by 35 cycles including a denaturation step at 95°C for 15 s and an annealing step of 1 min at 
62°C in a final volume of 5 µl. 
Statistical analysis 
The proportions of patients with clinical and CRP responses to infliximab were compared between genotypes 
using a χ2 or Fisher's exact test, as appropriate. Decreases in CDAI and CRP were compared across genotypes 
using an analysis of variance on the van der Waerden normal scores. For relative decreases in CRP, the analysis 
was first performed on the entire cohort, and then on the subgroup of patients having CRP concentration data at 
baseline within the two highest quartiles. Furthermore, as this analysis was intended as a confirmatory study of a 
previous one [6], a one-tailed test was also applied. 
Results 
FCGR3A genotypes and baseline characteristics 
Baseline characteristics of the ACCENT I population have been described previously [7]. In this substudy, 
95.3% of patients were Caucasian, 57.3% were women, and the median (range) age was 35 (18-76) years. 
Patients had a median (range) disease duration of 8 (0.2-38.9) years. Regarding disease location, 25.5% of 
patients had ileum involvement, 20.8% had the colon involved, and 53.7% had ileum and colon involvement. 
The median (range) baseline CDAI score was 293 (200-450), and the median (range) baseline CRP level was 0.8 
(0.4-16.2) mg/d. The proportions of patients with FCGR3A V/V, V/F, and F/F genotypes were 14.2, 43.6, and 
42.2%, respectively. No deviation was found from Hardy-Weinberg equilibrium. At baseline, there was no 
significant difference between genotypes as far as CDAI (306.2 ± 49.1, 300.8 ± 53.6, and 296.9 ± 56.1 for V/V 
V/F, and F/F patients, respectively) and CRP serum concentrations (2.1 ± 2.5, 1.9 ± 2.2, and 1.6 ± 2.1 mg/dl, for 
V/V, V/F, and F/F patients, respectively). 
FCGR3A genotypes according to clinical and biological response to infliximab 
At week 2, in the overall cohort, there was no significant difference in clinical or CRP response to infliximab 
when assessed by FCGR3A genotype (Table 1). 
The analysis of the subgroup both at baseline and at week 6 CRP values within the two highest quartiles (n = 
156) showed a trend toward a greater relative change in CRP at week 6 in V/V homozygotes (-79.4, -76.5, and     
-64.3%, in V/V, V/F, and F/F genotypes, respectively; P = 0.085; one-tailed P = 0.043). Numerical differences 
were already present at week 2 but were not statistically significant (Fig. 1). In this subgroup, all (95.8%) but one 
patient with V/V genotype had a decrease of at least 25% in CRP at week 6, while this was the case for only 
87.1% of  V/F patients and 79.0% of F/F patients (P = 0.12; one-tailed P =0.06). This trend was also evident at 
week 2 (96, 88.6, and 87.7%, for V/V, V/F, and F/F patients, respectively; P = 0.497). 
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Table 1    Clinical and CRP response 2 weeks after a single infusion of infliximab 5 mg/kg by FCGR3A genotype 
among the 344 ACCENT I substudy patients 
Genotype FCGR3A V/V FCGR3A V/F FCGR3A F/F P-value 
Patients evaluated 49 (14.2%) 150 (43.6%) 145 (42.2%)  
Clinical response (CDAI  ≥ 70) 61.2% 56.7% 66.9% 0.195 
Clinical remission (CDAI <150) 20.4% 26.0% 31.0% 0.314 
Median CDAI decrease -97.0 -84.5 -101.0 0.487 
Median CRP decrease -0.4 -0.2 -0.1 0.255 
Median % CRP change -43.7% -33.3% - 20.0% 0.195 
CRP, C-reactive protein; CDAI, Crohn's disease activity index. 
 
Fig. 1 : Median relative decrease in C-reactive protein (CRP) following the administration of infliximab 5 mg/kg 
at week 2 in patients with Crohn's disease in the ACCENT I study. Only patients with a CRP concentration within the two 
highest quartiles at both baseline and week 6 CRP were considered for this analysis (n= 156; CRP range: 0.9-16.2 mg/dl). Patients are 
separated into three groups according to FCGR3/4-158 genotype. At week 2, the largest decrease was observed in V/V patients and the 
smallest decrease in F/F patients, but this difference was not statistically significant. This difference reached a borderline level of 
significance by week 6 (P= 0.086; one-tailed P= 0.043). 
 
Discussion 
Our findings indicate an absence of association between FCGR34-158 polymorphism and clinical response to 
infliximab in CD. Furthermore, in this large cohort of patients from the ACCENT I study, there was also no 
strong influence on biological (CRP) response, although there was a numerical difference in the magnitude of the 
CRP decrease following infliximab therapy. In a previous study, there was a significant association between the 
same FCGR3A polymorphism and the proportion of patients having a decrease in CRP after infliximab, as well 
as with the magnitude of CRP decrease [6]. In that series of patients from the Belgian Expanded Access Program 
for infliximab in CD, there was also no strong association between polymorphism and infliximab clinical 
response, although in multivariate analysis of patients with elevated baseline CRP, immunosuppressant use and 
FCGR3A polymorphism were independently associated with a positive clinical response to infliximab. These 
data were therefore suggestive of an influence of this variant on the control of the inflammation induced by 
infliximab in CD. This hypothesis was reinforced by previous data showing a similar effect with another IgG1 
therapeutic monoclonal antibody, rituximab, in non-Hodgkin's lymphoma   [5],  and  by functional  data showing 
a  better affinity of the FcγRIIIa-158V allotype for IgGl and an ADCC EC50 at lower rituximab concentrations in 
V/V patients [9]. It was assumed that the analysis of a larger cohort would demonstrate a significant influence of 
this polymorphism on the clinical response to infliximab in CD patients. This was not, however, the case in the 
present large and very well-defined ACCENT I cohort. 
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FCGR3A polymorphism is not a practical marker to assist clinicians in defining the best candidates for 
infliximab treatment and has yet to find its place in the management of patients receiving infliximab. In this 
ACCENT I cohort, as in the Belgian cohort, the relative decrease in CRP was greatest in V/V homozygotes and 
lowest in F/F homozygotes. In these studies, discrepancies in the number of infliximab infusions and timing of 
response evaluations do not allow strict comparison or metaanalysis, the difference between genotypes was of 
the same magnitude. 
The mechanism of action of infliximab in CD appears to be multifactorial. Along with neutralizing soluble TNF-
α, inducing apoptosis of cells expressing membrane-bound TNF is the most well-characterized mechanism of 
action [2-4]. Other mechanisms however, including lysis of TNF-expressing cells by complement activation and 
ADCC, have also been suggested [1]. Although in-vivo data are lacking to demonstrate ADCC involvement in 
infliximab effect in CD, the ability of infliximab to bind transmembrane TNF-α has been clearly demonstrated 
[2,4,10]. Owing to the complexity of infliximab action in CD, it is unlikely that a single biological or clinical 
parameter would have a strong influence on the response to the agent. This is particularly true for clinical 
response, owing to the influence of subjective variables in the scores used in clinical evaluations and to the 
influence of factors not directly related to inflammation in the clinical evolution of the patients, for example, 
fibrotic stricture-related pain or functional diarrhea. Therefore, the finding of the same phenomenon (influence of 
FCGR3A genotype on CRP decrease) in two large independent cohorts is certainly of value and is not a trivial 
finding. Importantly, this finding may help further the understanding of the mechanism of action of infliximab in 
CD and even possibly assist in the design of new anti-TNF molecules. The precise mechanism by which this 
variant may influence response to infliximab in CD remains to be elucidated. Further study of the CRP gene 
located close to the FCGR3A gene, however, confirmed that the association seen in the Belgian cohort was 
indeed with the FCGR3A variants and not with the CRP gene itself [10]. With regard to the mechanism of this 
association, the most attractive hypothesis is more efficient destruction or a destruction at a lower concentration 
of membrane TNF-expressing cells by ADCC in W homozygous patients.  In this hypothesis, this variant would 
not create a dichotomy of response-non-response but rather enhance the response to infliximab in a subgroup of 
patients. The evolution of CRP decrease at weeks 2 and 6 (Fig. 1), suggests the possibility of a shorter duration 
of inflammation control in F/F homozygous patients. This may fit with the lower affinity of the FcγRIIIa-158F 
allotype for IgG1. As for rituximab, a higher concentration of infliximab would be needed for ADCC in these 
patients. In this hypothesis, the week-2 time point may be too early to discern a significant difference between 
genotypes. On the other hand, week-6 data are not as easy to interpret because patients in the ACCENT I study 
had received either one or two infusions of 5 mg/kg by this time point. In patients who received higher doses of 
infliximab, the influence of FCGR3A polymorphism may be attenuated. 
In conclusion, no association between the FCGR3A-158 polymorphism and the clinical response to infliximab in 
CD could be observed. Hence, this polymorphism has no direct clinical impact on the management of the 
patients. As previously suggested however, this polymorphism seems to influence the magnitude of CRP 
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